TRANSURETHRAL RESECTION WITH PERIOPERATIVE INSTILLATION OF INTERFERON-alpha OR EPIRUBICIN FOR THE PROPHYLAXIS OF RECURRENT PRIMARY SUPERFICIAL BLADDER CANCER: A PROSPECTIVE RANDOMIZED MULTICENTER STUDY-FINNBLADDER III

Abstract

A single 100 mg. dose of epirubicin given intravesically immediately after transurethral resection is safe, and significantly decreases the recurrence of primary superficial bladder cancer. A 50 million unit dose of interferon-alpha2b is well tolerated but it has no effect on recurrence as a single dose. The long-term effect of this treatment remains to be studied.